3.6.1.5: apyrase

This is an abbreviated version!
For detailed information about apyrase, go to the full flat file.

Reaction

Synonyms

5' ectonucleotidase, 5'-nucleotidase, adenosine diphosphatase, adenosine pyrophosphatase, adenylpyrophophatase, ADPase, APT102, Apy, Apy 1, Apy 2, APY-1, APY1, APY10, APY2, APY2-type apyrase, APY4, APY5, APY6, APY7, APY8, APY9, Apyrase, apyrase 2, APYRASE2, At1g14230, At1g14240, At1g14250, At2g02970, At3g04080, At5g18280, AtAPY1, AtAPY2, AtAPY3, AtAPY4, AtAPY5, AtAPY6, ATP diphosphohydrolase, ATP diphosphohyrolase, ATP-diphosphatase, ATP-diphosphohydrolase, ATP-diphosphohydrolase 2, ATPase, ATPase 2, ATPDase, ATPDase1, ATPDase2, BjAPY2, Ca2+-activated nucleoside diphosphatase, CApy, CD39, CD39 antigen, CD39-like ATP diphosphohydrolase, CD39L1, Def11, E-NTPDase, E-NTPDase 3, ecto-5'-nucleotidase, ecto-apyrase, ecto-ATP diphosphohydrolase, ecto-ATP-diphosphohydrolase, ecto-ATPase, ecto-ATPDase, ecto-NTPDase, Ecto-NTPDase1, ecto-nucleoside triphosphate diphosphohydrolase, ecto-nucleoside triphosphate diphosphohydrolase 1, ecto-nucleoside triphosphate diphosphohydrolase 2, ecto-nucleoside triphosphate diphosphohydrolase1, ecto-nucleoside triphosphate diphosphohydrolase2, ecto-nucleoside triphosphate diphosphohydrolase3, ecto-nucleoside triphosphate diphosphohydrolase8, ecto-nucleoside triphosphate-diphosphohydrolase, ecto-nucleoside-triphosphate-diphosphohydrolase, ectoapyrase, ectonucleoside triphosphate diphosphohydrolase, ectonucleoside triphosphate diphosphohydrolase 3, ectonucleotidase, ENTPD1, ENTPD2, ENTPD3, Entpd8, ENTPDase1, esctonucleoside triphosphate diphosphohydrolase 1, esctonucleoside triphosphate diphosphohydrolase 2, esctonucleoside triphosphate diphosphohydrolase 8, Golgi nucleoside diphosphatase, GS50, GS52, HB6, hCD39, LALP1, LBRM_15_0030, LicNTPDase-2, LINJ_15_0030, LmjF15.0030, LmNTPDase 1, Lpg1905, lumenal NDPase, Lymphoid cell activation antigen, More, MP67, MpAPY2, NTPase, NTPD1, NTPDase, NTPDase 1, NTPDase 2, NTPDase 3, NTPDase 5, NTPDase 6, NTPDase 8, NTPDase1, NTPDase1/CD39, NTPDase2, NTPDase2/CD39L1, NTPDase3, NTPDase8, nucleoside triphosphatase, nucleoside triphosphate diphosphohydrolase, nucleoside triphosphate diphosphohydrolase 1, nucleoside triphosphate diphosphohydrolase 2, nucleoside triphosphate diphosphohydrolase 8, nucleoside triphosphate diphosphohydrolase-1, NDPDase 1, nucleoside triphosphate diphosphohydrolase-2, nucleoside triphosphate diphosphohydrolase-3, nucleoside triphosphate diphosphohydrolase-8, nucleoside triphosphate disphophohydrolase, nucleoside triphosphate-diphosphohydrolase, nucleotide triphosphate diphosphohydrolase, PeAPY2, potato-specific apyrase, PsAPY1, psNTP9, r-NTPDase 1, r-NTPDase 2, r-NTPDase 3, r-NTPDase 8, Ruviapyrase, SCAN-1, snake venom apyrase, SolCD39/NTPDase1, soluble apyrase, soluble calcium-activated nucleotidase 1, soluble CD39, TaAPY1, TaAPY2, TaAPY3-1, TaAPY3-2, TaAPY3-3, TaAPY3-4, TaAPY5, TaAPY6, TaAPY7, XAPY

ECTree

     3 Hydrolases

         3.6 Acting on acid anhydrides

             3.6.1 In phosphorus-containing anhydrides

                3.6.1.5 apyrase

Advanced search results

Do not include text mining results

Include results (more...)

Include results (more...)

Results	in table
17	Activating Compound
855	AA Sequence
15	Application
1	CAS Registry Number
72	Cloned(Commentary)
6	Crystallization (Commentary)
1062	Disease/ Diagnostics
11	Expression
68	General Information
7	General Stability
2	IC50 Value
277	Inhibitors
33	kcat/KM [mM/s]
16	Ki Value [mM]
154	KM Value [mM]
135	Localization
186	Metals/Ions
74	Molecular Weight [Da]
252	Natural Substrates/ Products (Substrates)
1	Organic Solvent Stability
230	Organism
8	Pathway
72	PDB ID
64	pH Optimum
17	pH Range
29	pI Value
20	Posttranslational Modification
48	Protein Variants
49	Purification (Commentary)
3	Reaction
1	Reaction Type
198	Reference
3	Renatured (Commentary)
289	Source Tissue
121	Specific Activity [micromol/min/mg]
4	Storage Stability
721	Substrates and Products (Substrate)
69	Subunits
343	Synonyms
1	Systematic Name
46	Temperature Optimum [°C]
5	Temperature Range [°C]
3	Temperature Stability [°C]
55	Turnover Number [1/s]

Application

print visible entries

print all entries

Go back to the abbreviated version
of the Enzyme Summary Page.

Application on EC 3.6.1.5 - apyrase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.

top print hide show all columns Go to Application Search

Please wait a moment until the data is sorted. This message will disappear when the data is sorted.

APPLICATION

ORGANISM

UNIPROT

COMMENTARY

LITERATURE

agriculture

Glycine max

-

expression of enzyme in in Lotus japonicus results in enhanced nodulation that correlates with expression level

670584

analysis

4 entries

drug development

2 entries

medicine

7 entries

pharmacology

Aedes aegypti

-

the enzyme may serve as a therapeutic agent for inhibition of platelet-mediated thrombosis

670643

analysis

Leishmania infantum

A4HWA0

immune sera that recognize specifically the B domain of NTPDase 1 are produced against synthetic peptides (LbB1LJ and LbB2LJ) derived from this domain of NTPDase from Leishmania brasiliensis. The polyclonal antibodies have effective anti-leishmanial effect, reducing significantly in vitro promastigotes growth (21-25%), an antiproliferative effect is also demonstrated by immune sera produced against recombinant r-pot B domain, and two other synthetic peptides (potB1LJ and potB2LJ). In addition, using these biomolecules in ELISA technique, IgG1 and IgG2 subclasses reactivities of either healthy dogs or infected by Leishmania infantum and classified clinically as asymptomatic, oligosymptomatic and symptomatic are tested. Analysis of distinct IgG1 and IgG2 seropositivities patterns suggest antibody subclasses binding epitopes along B domain for protection against infection, indicating this domain as a tool for prophylactic and immunotherapeutic investigations

758530

analysis

Leishmania braziliensis

A4H7X3

immune sera that recognize specifically the B domain of NTPDase 1 are produced against synthetic peptides (LbB1LJ and LbB2LJ) derived from this domain of NTPDase from Leishmania brasiliensis. The polyclonal antibodies have effective anti-leishmanial effect, reducing significantly in vitro promastigotes growth (21-25%), an antiproliferative effect is also demonstrated by immune sera produced against recombinant r-pot B domain, and two other synthetic peptides (potB1LJ and potB2LJ). In addition, using these biomolecules in ELISA technique, IgG1 and IgG2 subclasses reactivities of either healthy dogs or infected by Leishmania infantum and classified clinically as asymptomatic, oligosymptomatic and symptomatic are tested. Analysis of distinct IgG1 and IgG2 seropositivities patterns suggest antibody subclasses binding epitopes along B domain for protection against infection, indicating this domain as a tool for prophylactic and immunotherapeutic investigations

758530

analysis

Solanum tuberosum

P80595

usage of the enzyme in a two-dimensional array ATP/ADP sensitive image sensor, with a uniform distribution of chemically immobilized apyrase (via two different methods (3-APTES and CEST)). The enzyme sensor changes ATP into AMP, and the concentration of ATP reduces with time. The time-dependent profile of the potential response is different from the common ion sensor on which the concentration of the analyte ion is constant at an equilibrium state. Two ways of the measurement are used: 1. the addition measurement and 2. the steady measurement, overview

756325

analysis

Leishmania infantum MHOM/BR/1972/BH46

-

immune sera that recognize specifically the B domain of NTPDase 1 are produced against synthetic peptides (LbB1LJ and LbB2LJ) derived from this domain of NTPDase from Leishmania brasiliensis. The polyclonal antibodies have effective anti-leishmanial effect, reducing significantly in vitro promastigotes growth (21-25%), an antiproliferative effect is also demonstrated by immune sera produced against recombinant r-pot B domain, and two other synthetic peptides (potB1LJ and potB2LJ). In addition, using these biomolecules in ELISA technique, IgG1 and IgG2 subclasses reactivities of either healthy dogs or infected by Leishmania infantum and classified clinically as asymptomatic, oligosymptomatic and symptomatic are tested. Analysis of distinct IgG1 and IgG2 seropositivities patterns suggest antibody subclasses binding epitopes along B domain for protection against infection, indicating this domain as a tool for prophylactic and immunotherapeutic investigations

-

drug development

Trypanosoma cruzi

Q6QHT8

Ecto-NTPDase1 is a target candidate in chemotherapy of Chagas disease

700876

drug development

Homo sapiens

O75355, P49961, Q5MY95, Q9Y5L3

the NTPDase isozymes are targets for development of potent and selective drug-like NTPDase inhibitors

755781

medicine

Homo sapiens

-

enzyme in lipid vesicles effectively inhibits platelet aggregation when activated by ADP, collagen, or thrombin, and also promotes platelet disaggregation. Treatment with enzyme lipid vesicles preserves platelet counts after thromboplastin injection

670068

medicine

Aedes aegypti

-

enzyme inhibits ADP- collagen- and thrombin-induced human platelet aggregation in dose-dependent manner, use as a therapeutic agent for inhibition of platelet-mediated thrombosis

670643

medicine

Solanum tuberosum

P80595

significant IgG antibody reactivity was observed in sera from patients with American cutaneous leishmaniasis and schistosomiasis using potato apyrase as antigen, development of drug targets or molecular markers

700566

medicine

Schistosoma mansoni

A1BXT9

significant IgG antibody reactivity was observed in sera from patients with American cutaneous leishmaniasis and schistosomiasis using Schistoma mansoni adult worm or egg as antigen, development of drug targets or molecular markers

700566

medicine

Phlebotomus duboscqi

Q06K73, Q06K77

its unique enzymatic activity makes the salivary apyrase an attractive candidate as a therapeutic agent for the treatment of thrombotic pathologies

712658

medicine

Homo sapiens

O75355, P49961, Q5MY95, Q9Y5L3

activation of CD39 has potential for treating inflammatory diseases, while inhibition is suggested as a strategy for the immunotherapy of cancer

755782

medicine

Homo sapiens

P49961

augmenting CD39 activity is a potential therapy to improve both short- and long-term outcomes of ischemia-reperfusion injury (IRI) by reducing the extracellular concentration of proinflammatory ATP and promoting adenosine generation. In mouse models of IRI, treatment with soluble CD39 (apyrase) or expression of a human CD39 (hCD39) transgene in mice (CD39Tg mice) reduce the severity of acute kidney injury (AKI) as evidenced by decreased serum creatinine and reduced tubular injury score at 24 hours

758513